Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, focusing on developing innovative therapies for immune-related diseases. Recently, Graig Suvannavejh from Mizuho Securities set a new price target of $30 for CRVS, which is a 46.06% increase from its current trading price of $20.54.
CRVS has seen a remarkable 209% surge in its stock price over the past month. This increase follows positive results from a Phase I study of their lead candidate, soquelitinib, for treating moderate to severe atopic dermatitis. The study showed a 72% reduction in the Eczema Area and Severity Index (EASI) by day 56, with no serious adverse events.
The promising data from the study has fueled investor optimism, contributing to the substantial rally in CRVS stock. The company also closed an upsized public offering of its common stock, raising approximately $201 million. These funds will support working capital, capital expenditures, and research and development, particularly for its Phase 3 T cell lymphoma program.
Corvus's recent Phase I results for soquelitinib, an oral drug targeting atopic dermatitis, were conducted in a blinded, placebo-controlled trial. The study involved patients who had previously undergone systemic therapy. The findings confirm earlier positive signals, reinforcing soquelitinib's potential as a "first-in-class" selective ITK inhibitor.
Currently, CRVS is trading at $20.54, reflecting a 6.97% decrease with a change of $1.54. The stock has fluctuated between $20.34 and $22.27 today. Over the past year, CRVS reached a high of $26.95 and a low of $2.54. The company's market capitalization is approximately $1.53 billion, with a trading volume of 3,130,487 shares on the NASDAQ exchange.
